In Vivo AI Platforms

PsychoGenics’ Cube Technologies: Revolutionizing Neuropsychiatric Drug Discovery
CNS disorders impact hundreds of millions of patients who not only suffer from severely disabling conditions but who also face ineffective or unsafe treatment options. The human and societal impact of mental illness is profound, affecting 1 in 5 individuals during their lifetime. This can lead to consequences such as homelessness, incarceration, and the loss of trillions of dollars in productivity. There has been an absence of new treatment mechanisms over the past few decades primarily driven by the failure of the target-based approach, which looks for target-selective treatments. Neuropsychiatric disorders, however, are inherently complex, reflecting an interplay of genes, epigenetic factors, compensatory mechanisms, and environmental stressors, which are unlikely to respond to single-target pharmacology. A viable alternative is phenotypic drug discovery, which identifies treatments based on their ability to rescue a disease phenotype in a cell or organism. Responding to this unmet need, in 2002, PsychoGenics embarked on a journey to apply automation and AI to drug discovery based on mouse behavior.

SmartCube®

SmartCube® is an automated, high-throughput testing platform that employs machine learning to process millions of data points collected from mice to extract behavioral signatures of novel compounds, and by comparing to a comprehensive database of reference compounds, make predictions about their therapeutic potential.

NeuroCube®

NeuroCube® detects and evaluates changes in gait to assess the impact of treatments on motor impairment disorders and pain in both rats and mice.

PhenoCube®

PhenoCube® is a platform where mice are observed continuously, day and night, allowing for the tracking of their social, circadian, motor, and cognitive behaviors over an extended period.

eCube®

eCube® is a pharmaco-EEG platform that collects data from novel compounds and compares their signatures against a comprehensive database of marketed drugs, enabling the prediction of the therapeutic utility of these compounds, and the discovery of EEG biomarkers.

Services

Partner with PsychoGenics and Accelerate Your Preclinical Mental Illness Research

We believe in the power of collaboration and work closely with you to design highly customized studies that align with your specific research goals. PsychoGenics’ team of early-stage mental illness drug development experts advise you on the most suitable approach, ensuring a tailored experience and the best possible outcome. With our deep understanding of rodent models, advanced technologies, and commitment to customized solutions, we offer the ideal partnership for driving your mental illness drug development program.